From Wikipedia, the free encyclopedia

Clinical data
Pronunciation/lænˈsprəzl/ lan-SOH-prə-zohl
Trade namesPrevacid, others
Other namesAG 1749
License data
Routes of
By mouth, intravenous
Drug classProton pump inhibitor
ATC code
Legal status
Legal status
  • AU: S2, S3, & S4
  • UK: POM (Prescription only)
  • US: OTC / Rx-only[2]
Pharmacokinetic data
Bioavailability80% or more
Protein binding97%
MetabolismLiver (CYP3A4- and CYP2C19-mediated)
Elimination half-life1.0–1.5 hours
ExcretionKidney and fecal
  • (RS)-2-([3-methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl)-1H-benzo[d]imidazole
CAS Number
PubChem CID
CompTox Dashboard (EPA)
ECHA InfoCard100.173.220 Edit this at Wikidata
Chemical and physical data
Molar mass369.36 g·mol−1
3D model (JSmol)
ChiralityRacemic mixture
Melting point178 °C (352 °F) (decomposes)
  • FC(F)(F)COc1ccnc(c1C)CS(=O)c2[nH]c3ccccc3n2
  • InChI=1S/C16H14F3N3O2S/c1-10-13(20-7-6-14(10)24-9-16(17,18)19)8-25(23)15-21-11-4-2-3-5-12(11)22-15/h2-7H,8-9H2,1H3,(H,21,22) checkY

Lansoprazole, sold under the brand name Prevacid among others, is a medication which reduces stomach acid.[3] It is a proton pump inhibitor (PPI), used to treat peptic ulcer disease, gastroesophageal reflux disease, and Zollinger–Ellison syndrome.[4] Its effectiveness is similar to that of other PPIs.[5] It is taken by mouth.[3] Onset is over a few hours and effects last up to a couple of days.[3]

Common side effects include constipation, abdominal pain, and nausea.[3][2] Serious side effects may include osteoporosis, low blood magnesium, Clostridium difficile infection, and pneumonia.[3][2] Use in pregnancy and breastfeeding is of unclear safety.[1] It works by blocking H+/K+-ATPase in the parietal cells of the stomach.[3]

Lansoprazole was patented in 1984 and came into medical use in 1992.[6] It is available as a generic medication.[4] In 2020, it was the 191st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[7][8]

Medical uses[edit]

Lansoprazole is used for treatment of:[2]

There is no good evidence that it works better than other PPIs.[5]

Side effects[edit]

Side effects of PPIs in general[10] and lansoprazole in particular[11] may include:[2]

PPIs may be associated with a greater risk of hip fractures and Clostridium difficile-associated diarrhea.[2]: 22 


Lansoprazole interacts with several other drugs, either due to its own nature or as a PPI.[15]

Lansoprazole possibly interacts with, among other drugs:


It is a racemic 1:1 mixture of the enantiomers dexlansoprazole and levolansoprazole.[17] Dexlansoprazole is an enantiomerically pure active ingredient of a commercial drug as a result of the enantiomeric shift. Lansoprazole's plasma elimination half-life (1.5 h) is not proportional to the duration of the drug's effects to the person (i.e. gastric acid suppression).[18]


Lansoprazole was originally synthesized at Takeda and was given the development name AG 1749.[19] Takeda patented it in 1984 and the drug launched in 1991.[20] In the United States, it was approved for medical use in 1995.[21]

Society and culture[edit]

Prevacid 30 mg


The lansoprazole molecule is off-patent and so generic drugs are available under many brand names in many countries;[22] there are patents covering some formulations in effect as of 2015.[23] Patent protection expired on 10 November 2009.[24][25]


Since 2009, lansoprazole has been available over the counter (OTC) in the U.S. as Prevacid 24HR[26][27] and as Lansoprazole 24HR.[28] In Australia, it is marketed by Pfizer as Zoton.[29]


In vitro experiments have shown that lansoprazole binds to the pathogenic form of tau protein.[30] As of 2015 laboratory studies were underway on analogs of lansoprazole to explore their use as potential PET imaging agents for diagnosing tauopathies including Alzheimer's disease.[30]


  1. ^ a b "Lansoprazole Use During Pregnancy". Retrieved 3 March 2019.
  2. ^ a b c d e f "Lansoprazole capsule, delayed release pellets". DailyMed. U.S. National Library of Medicine. 11 October 2016. Retrieved 31 December 2019.
  3. ^ a b c d e f "Lansoprazole Monograph for Professionals". American Society of Health-System Pharmacists. Retrieved 3 March 2019.
  4. ^ a b British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. pp. 79–80. ISBN 9780857113382.
  5. ^ a b "Comparative effectiveness of proton pump inhibitors". Therapeutics Initiative. Dept of Anesthesiology, Pharmacology & Therapeutics, Faculty of Medicine, University of British Columbia. 28 June 2016. Retrieved 14 July 2016.
  6. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 445. ISBN 9783527607495.
  7. ^ "The Top 300 of 2020". ClinCalc. Retrieved 7 October 2022.
  8. ^ "Lansoprazole - Drug Usage Statistics". ClinCalc. Retrieved 7 October 2022.
  9. ^ Hirschowitz BI, Mohnen J, Shaw S (August 1996). "Long-term treatment with lansoprazole for patients with Zollinger-Ellison syndrome". Alimentary Pharmacology & Therapeutics. 10 (4): 507–522. doi:10.1046/j.1365-2036.1996.10152000.x. PMID 8853754. S2CID 10668517.
  10. ^ "1.3.5 Proton pump inhibitors". British National Formulary.
  11. ^ "Lansoprazole". British National Formulary.
  12. ^ "Prevacid (Lansoprazole) Drug Information: Side Effects and Drug Interactions - Prescribing Information". RxList. Retrieved 9 February 2016.
  13. ^ K C Singhal & S Z Rahman, Lansoprazole Induced Adverse Effects on the Skin, Indian Medical Gazette, July 2001, Vol. CXXXV. N0. 7: 223-225
  14. ^ Sterry W, Assaf C (2007). "Erythroderma". In Bolognia JL (ed.). Dermatology. St. Louis: Mosby. p. 154. ISBN 978-1-4160-2999-1..
  15. ^ "Lansoprazole interactions". British National Formulary.
  16. ^ Piscitelli SC, Goss TF, Wilton JH, D'Andrea DT, Goldstein H, Schentag JJ (September 1991). "Effects of ranitidine and sucralfate on ketoconazole bioavailability". Antimicrobial Agents and Chemotherapy. 35 (9): 1765–1771. doi:10.1128/aac.35.9.1765. PMC 245265. PMID 1952845.
  17. ^ "Pharmacy Benefit Update". Retrieved 2 July 2014.
  18. ^ "Prevacid Pharmacology, Pharmacokinetics, Studies, Metabolism". 2007. Archived from the original on 16 August 2000. Retrieved 14 April 2007.
  19. ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 102. ISBN 9783527607495.
  20. ^ Chorghade MS (2006). Drug Discovery and Development, Volume 1: Drug Discovery. John Wiley & Sons. p. 201. ISBN 9780471780090.
  21. ^ "Lansoprazole". Mosby's Drug Consult. Archived from the original on 8 February 2009.
  22. ^ "International availability of lansoprazole". Retrieved 3 February 2015.
  23. ^ "Generic lansoprazole". Retrieved 3 February 2015.
  24. ^ "Prevacid Drug Profile". Retrieved 30 April 2020.
  25. ^ Witkowski W (7 November 2008). "Teva to release Prevacid version when patent expires". Market Watch. Dow Jones.
  26. ^ "Prevacid 24 HR- lansoprazole capsule, delayed release". DailyMed. 7 August 2019. Retrieved 31 December 2019.
  27. ^ "Prevacid 24 HR- lansoprazole capsule, delayed release". DailyMed. U.S. National Library of Medicine. 11 December 2019. Retrieved 31 December 2019.
  28. ^ "Lansoprazole 24 HR- lansoprazole capsule, delayed release". DailyMed. U.S. National Library of Medicine. 21 December 2017. Retrieved 31 December 2019.
  29. ^ "Zoton FasTabs". NPS MedicineWise. 2 September 2019. Retrieved 24 April 2022.
  30. ^ a b Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC (January 2015). "Tau imaging: early progress and future directions". The Lancet. Neurology. 14 (1): 114–124. doi:10.1016/s1474-4422(14)70252-2. PMID 25496902. S2CID 10502833.

External links[edit]

  • "Lansoprazole". Drug Information Portal. U.S. National Library of Medicine.